Home/Pipeline/VNX-205

VNX-205

Prostate Cancer

PreclinicalActive

Key Facts

Indication

Prostate Cancer

Phase

Preclinical

Status

Active

Company

Vironexis Biotherapeutics

About Vironexis Biotherapeutics

Vironexis Biotherapeutics, founded in 2021, is developing a transformative platform for AAV-delivered T-cell immuno-gene therapy. The company's TransJoin™ platform is designed to create off-the-shelf, single-infusion therapies that engineer a patient's T cells in vivo to target and kill cancer cells, bypassing the need for complex ex vivo cell manufacturing. Its pipeline includes over ten preclinical programs targeting blood cancers, solid tumors, and cancer prevention, with its lead asset, VNX-101 for CD19+ leukemias and lymphomas, having received FDA IND clearance and multiple regulatory designations. The company is led by a founding team with deep expertise in gene therapy development and oncology.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders

Other Prostate Cancer Drugs

Drug	Company	Phase	Status
APVO442	Aptevo Therapeutics	Preclinical	Active
APVO452	Aptevo Therapeutics	Discovery	Active
BIO 300	Humanetics Corp.	Not Specified	Active
Opaganib	RedHill Biopharma	Phase 2	Active
MagSense™ PSMA Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
CROES Registry	AngioDynamics	Post-Market Registry	Active
Cannabics® PRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
HDP-103	Heidelberg Pharma	Preclinical	Active
ENV105	Kairos Pharma	Phase 2	Active
AI for Prostate Cancer	Invenio Imaging	Research	Active